Shopping News / Articles
Tai Med Completes Phase 2b Enrollment for TMB-365/380 HIV Therapy
19+ hour, 2+ min ago (385+ words) The Clinical Trial Vanguard Tai Med Completes Phase 2b Enrollment for TMB-365/380 HIV Therapy Every broad-neutralizing antibody (b NAb) combination in HIV development has stumbled on the same practical obstacle: resistance screening. Patients require pre-treatment genotyping to confirm viral susceptibility before…...
Aktis Oncology Reports First-in-Human Data for AKY-2519 in B7-H3 Tumors
19+ hour ago (458+ words) The Clinical Trial Vanguard Aktis Oncology Reports First-in-Human Data for AKY-2519 in B7-H3 Tumors Among the most closely watched toxicity signals in actinium-225 radiopharmaceuticals, salivary gland dose has derailed or constrained multiple programs " which makes the 4. 2 Gy RBE predicted salivary gland…...
China Approves Toripalimab Plus Disitamab Vedotin for HER2+ Urothelial Cancer
19+ hour ago (407+ words) The Clinical Trial Vanguard China Approves Toripalimab Plus Disitamab Vedotin for HER2+ Urothelial Cancer A hazard ratio of 0. 36 for progression-free survival is not a modest improvement over chemotherapy " it is a near-dismantling of the comparator arm. The RC48-C016 trial, which drove China's…...
Tedopi Plus Pembrolizumab Shows PFS Benefit in Recurrent Ovarian Cancer
19+ hour, 3+ min ago (21+ words) Tedopi Plus Pembrolizumab achieves 47% risk reduction in recurrent ovarian cancer, extending median PFS to 4. 1 months in chemotherapy-exhausted patients....
LUMA trial shows BIIB122 failed to slow Parkinson's despite target engagement
19+ hour, 2+ min ago (22+ words) LUMA trial shows BIIB122 failed to slow Parkinson's despite achieving robust target engagement in 648 early-stage patients over 48144 weeks....
Risvodetinib for Parkinson's: End of Phase 2 FDA Meeting Details Announced
1+ year, 2+ day ago (57+ words) ABLi Therapeutics recently completed an End of Phase 2 meeting with the FDA to discuss results from their Parkinson's disease trial and plan their Phase 3 program. The company's drug, risvodetinib, showed promising results in Phase 2, achieving nominal significance in key measures…...
RESP-X shows safety, reduced exacerbations in bronchiectasis study
19+ hour, 1+ min ago (220+ words) The Clinical Trial Vanguard RESP-X shows safety, reduced exacerbations in bronchiectasis study A 28. 8-day half-life is an unusual asset in anti-infective development, and it is precisely that pharmacokinetic property that makes the RESP-X Phase IIa results worth examining beyond the…...
The CHMP's May 2026 Output Signals a Structural Shift in European Drug Development " Sponsors Should Take Notes Now
19+ hour, 8+ min ago (177+ words) The 13 indication extensions carry equal strategic weight. Extensions are not administrative housekeeping " they are clinical evidence packages that survived full CHMP scientific scrutiny, and each one represents a pivotal trial that was designed years earlier with precisely this EU pathway…...
Zongertinib Shows Early Symptom Relief in LUNG-1 PRO Trial
1+ day, 19+ hour ago (441+ words) The Clinical Trial Vanguard Zongertinib Shows Early Symptom Relief in LUNG-1 PRO Trial Seventy-one patients is a small number on which to anchor a regulatory narrative, yet the Beamion LUNG-1 PRO data presented at ASCO 2026 matter precisely because zongertinib already…...
When Phase 2b Wins and Phase 3 Fails: The Biomarker Stratification Crisis Hidden Inside Astegolimab's COPD Data
1+ day, 19+ hour ago (739+ words) The Clinical Trial Vanguard When Phase 2b Wins and Phase 3 Fails: The Biomarker Stratification Crisis Hidden Inside Astegolimab's COPD Data Three respiratory biologics have now entered Phase 3 COPD trials with strong Phase 2b signals, and three times the confirmatory data has come…...
Shopping
Please enter a search for detailed shopping results.